- Recent Funding
- Investors
- Curie.Bio
Curie.Bio portfolio
Curie.Bio has 1 portfolio company on record at Recent Funding, with 1 investment in the last 12 months.
About this page
It is a venture capital firm based in Cambridge, US, founded in 2022. Its most recent investment on record is R1 Therapeutics's $77.5M Series A round in March 2026, alongside DaVita Venture Group, U.S. Renal Care, Abingworth and 2 others. That company is in Health and bio.
About Curie.Bio
What Curie.Bio invests in
- Health and bio · 1 · 100%
How Curie.Bio invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series A | 1 100% | $77.5M |
Curie.Bio portfolio companies
RR1 Therapeutics$77.5MSeries A · Mar 2026
| Company | Round with Curie.Bio | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series A · $77.5M | $158M | Sep 30, 2026 Series A |
Most frequent co-investors
AAbingworth1 shared round · last Mar 17, 2026
SSymBiosis1 shared round · last Mar 17, 2026
FF-Prime Capital1 shared round · last Mar 17, 2026
DDaVita Venture Group1 shared round · last Mar 17, 2026
UU.S. Renal Care1 shared round · last Mar 17, 2026
Similar investors
IIzou Partners2 companies · 2 deals in 12 mo
- TThe Ljungstrom Family Office2 companies · 2 deals in 12 mo
OO'Shaughnessy Ventures3 companies · 1 deal in 12 mo
SSide Stage Ventures3 companies
AAble Partners4 companies · 1 deal in 12 mo
GGenoa Ventures5 companies · 4 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 1 round on Recent Funding that name Curie.Bio. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Curie.Bio, which is a subset of its real portfolio. API: /api/v1/investors/curie-bio (get a free API key). More: the most active VC firms and new venture capital funds.